AllianceBernstein’s Trevi Therapeutics TRVI Stock Holding History

AllianceBernstein’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.1M	Sell	2,355,453 -490,019	-17%	-$7.13M	0.01%	802
2026 Q1	$35.6M	Sell	2,845,472 -237,514	-8%	-$2.66M	0.01%	704
2025 Q4	$38.6M	Sell	3,082,986 -1,209,465	-28%	-$14M	0.01%	708
2025 Q3	$39.3M	Buy	4,292,451 +11,096	+0.3%	+$83.2K	0.01%	684
2025 Q2	$23.4M	Buy	4,281,355 +4,259,015	+19,065%	+$26.5M	0.01%	845
2025 Q1	$141K	Buy	22,340 +6,900	+45%	+$32.9K	﹤0.01%	3011
2024 Q4	$63.6K	Hold	15,440	–	–	﹤0.01%	3170
2024 Q3	$51.6K	Hold	15,440	–	–	﹤0.01%	3188
2024 Q2	$46K	Buy	+15,440	New	+$42.9K	﹤0.01%	3197

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

AllianceBernstein's TRVI Position: Q2 2026 in Review

AllianceBernstein reduced its Trevi Therapeutics (TRVI) stake by 17% in Q2 2026, selling an estimated $7.13M and leaving 2,355,453 shares worth $28.1M. The position accounts for 0.01% of the portfolio, ranked #802.

AllianceBernstein first reported a position in TRVI in Q2 2024 and has held it in 9 quarters since. The position peaked at $39.3M in Q3 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

AllianceBernstein held 2,355,453 shares of Trevi Therapeutics worth $28.1M as of Q2 2026.
AllianceBernstein sold 490,019 Trevi Therapeutics shares in Q2 2026, an estimated $7.13M.
Trevi Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #802 holding.
AllianceBernstein first reported a position in Trevi Therapeutics in Q2 2024 and has held it in 9 quarters since.
AllianceBernstein's Trevi Therapeutics position peaked at $39.3M in Q3 2025.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.